ProBio, a subsidiary of GenScript Biotech Corporation, is a global Contract Development and Manufacturing Organization (CDMO) that accelerates the discovery, development, and commercialization of biologics and advanced therapies. Combining innovative discovery platforms with integrated development and GMP manufacturing capabilities, ProBio provides end-to-end solutions across antibodies, recombinant proteins, plasmid DNA, mRNA, viral vectors, and in vivo CAR-T therapies.
From target discovery and lead optimization through process development, clinical supply, and commercial manufacturing, ProBio helps partners advance complex programs with speed, quality, and confidence. Its scalable technology platforms, global manufacturing network, and deep scientific expertise enable efficient progression from concept to clinic and beyond.
Through a collaborative, risk-sharing approach, ProBio also offers flexible licensing and co-development opportunities, helping biotech and pharmaceutical companies reduce development risk, accelerate timelines, and bring innovative therapies to patients faster.